Recent Updates
Recently added Catalysts
TGTX Positive Sentiment

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: TG Therapeutics presented updated clinical data at MSToronto2026. The company shared seven-year follow-up results from the ULTIMATE I & II trials. It also reported Phase 1 subcutaneous BRIUMVI data. Additional updates covered the Phase 3 ENHANCE trial and the ENABLE real-world study.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seven-year follow-up data shows promising results.
  • Multiple presentations highlight BRIUMVI's effectiveness.
  • New data from Phase 1 and Phase 3 trials presented.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
17.8%
average across 2 past catalysts
Lead asset
Azercabtagene zapreleucel
Phase 1 · B-cell Mediated Autoimmune Disorders

Full Press Release Details

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentations highlighting BRIUMVI data. Additionally, the abstract is now available for the late-breaking oral presen

Frequently Asked Questions

What data did TG Therapeutics present at MSToronto2026?

The company presented seven-year follow-up data from ULTIMATE I & II trials and new findings from Phase 1 and Phase 3 studies.

What is BRIUMVI?

BRIUMVI is a treatment being studied by TG Therapeutics for multiple sclerosis.

What trials were highlighted in the presentations?

The presentations included data from the ULTIMATE trials, ENHANCE trial, and ENABLE real-world study.

What is the significance of the seven-year follow-up data?

It provides long-term insights into the effectiveness and safety of the treatments.

ShareAdd on Google
Tags: TGTX TG Therapeutics BRIUMVI multiple sclerosis MSToronto2026 clinical trials
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$552M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Azercabtagene zapreleucelPhase 1
B-cell Mediated Autoimmune Disorders →

Catalyst track record

+40%
best trade around TGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TGTX.

See every catalyst's timing & PoA →